Insider Selling: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Sells $500,500.00 in Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the transaction, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This trade represents a 16.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Sensei Biotherapeutics Trading Down 1.5%

NASDAQ:SNSE opened at $15.85 on Thursday. Sensei Biotherapeutics, Inc. has a twelve month low of $5.60 and a twelve month high of $36.76. The company has a 50-day moving average of $25.55 and a 200-day moving average of $18.70. The firm has a market cap of $21.24 million, a price-to-earnings ratio of -0.11 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83). On average, research analysts forecast that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SNSE. Renaissance Technologies LLC boosted its holdings in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after buying an additional 1,100 shares during the period. Bank of America Corp DE boosted its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the period. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the first quarter worth about $4,188,000. Finally, Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the first quarter worth about $22,758,000. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday, April 21st. Loop Capital set a $50.00 target price on shares of Sensei Biotherapeutics in a report on Thursday, May 28th. Cantor Fitzgerald initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, May 29th. They issued an “overweight” rating for the company. Citigroup initiated coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $46.25.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.